Celmatix is a biotechnology company focused on helpingphysicians guide patients to treatments that maximize their personal reproductive potential.
It announced six research presentations at the annual meeting of the American Society for Reproductive Medicine (ASRM), being held October 1217 in Boston.
In Vitro Fertilization (IVF)
Encyclopedia section of medindia gives a brief introduction to infertility and reproduction
Advertisement
Among the data presented was a new study suggesting that up to 25 percent of patients may be discontinuing assisted reproductive therapies such as in vitro fertilization (IVF) early, while they still have a good chance of having a baby. The clinical study, which was performed on a dataset of over 6,000 patients from study coauthors Reproductive Medicine Associates of New York, showed that 68 percent of women conceived within two cycles.
For those who did not conceive in that time frame and chose to discontinue treatment, the data suggested that more than half (60 percent) would have become pregnant if they had proceeded with an additional two treatment cycles. Other Celmatix findings being presented at ASRM include data on genetic markers related to currently unexplained female infertility and IVF success; factors correlated with higher risk of ectopic pregnancy; and an analytical model that predicts the estimated number of cycles needed by a particular couple to achieve live birth using various fertility treatments.
![Higher Breast Cancer Risk for Women Who Give Birth to Multiple Babies After IVF]( "Higher Breast Cancer Risk for Women Who Give Birth to Multiple Babies After IVF")
A large study shows women who give birth to multiple babies following IVF treatment are at a higher risk of breast cancer than those giving birth to singletons or who remain childless.
"We are excited to have this opportunity to present our research findings at ASRM, especially our finding that most patients who are initially unsuccessful with fertility treatments still have a significant chance of having a baby," said Piraye Yurttas Beim, PhD, Founder and Chief Executive Officer of Celmatix. "There are so many unanswered questions about why some women struggle with fertility. These questions create difficult decisions for women and their healthcare providers. Our goal is to offer tools and resources that make this process as informed and evidencebased as possible."
The oral abstracts presented by Celmatix were:
Higher Breast Cancer Risk for Women Who Give Birth to Multiple Babies After IVF
A large study shows women who give birth to multiple babies following IVF treatment are at a higher risk of breast cancer than those giving birth to singletons or who remain childless.
Advertisement
"We are excited to have this opportunity to present our research findings at ASRM, especially our finding that most patients who are initially unsuccessful with fertility treatments still have a significant chance of having a baby," said Piraye Yurttas Beim, PhD, Founder and Chief Executive Officer of Celmatix. "There are so many unanswered questions about why some women struggle with fertility. These questions create difficult decisions for women and their healthcare providers. Our goal is to offer tools and resources that make this process as informed and evidencebased as possible."
The oral abstracts presented by Celmatix were:
- Patients Discontinue Assisted Reproductive Technology (ART) Too Early: The Results of a Large Multiyear Cohort Study
- A Novel Role for Genomic Copy Number Variants in Female Infertility
- Accurate Prediction of the Number of Cycles to Achieve Live Birth
- Improved Determination of Ectopic Pregnancy Risks in Patients Undergoing In Vitro Fertilization Using TimeToEvent Models
- Whole Genome Sequencing for Female Infertility Biomarker Discovery
- Targeted Resequencing Sheds Light on the Etiology of Unexplained Female Infertility
Source: Eurekalert
Study Explains Adverse Effects of Phthalates on Ovarian Response to IVF
Among a group of industrial chemicals shown in some studies to have adverse effects on reproductive health and development, particularly in themale are phthalates.
Advertisement
 Simplified IVF Treatment Could Cost Around 200 EurosOffering hope to millions of infertile couples in the developing world, a simplified lab can slash the cost of in-vitro fertilisation treatment to around 200 euros ($256), a conference heard on Monday. | Advertisement
|
Advertisement
Recommended Readings
Latest Research News
The discovery deepens our understanding of m6A biology and stress granule formation, with implications for neurodegenerative diseases.
Trouble with sleep and the body's clock may increase your risk for Parkinson's, as per a new study.
New study uncovers a link between nocturnal hot flashes and Alzheimer's risk in menopausal women, suggesting a potential biomarker.
Our discovery revealed that a minority of individuals attributed their chronic pain to their brain's involvement.
Relative Energy Deficiency in Sport syndrome is overlooked by athletes and can be worsened by 'sports culture' due to its perceived short-term performance benefits.
